Denali Therapeutics Inc. filings document regulatory, financial and governance disclosures for a biotechnology company developing blood-brain-barrier-crossing therapeutics. Recent 8-K reports record operating results, FDA approval and launch-related disclosures for AVLAYAH™, clinical pipeline updates, and material events tied to collaboration agreements and royalty funding arrangements.
Denali’s proxy materials cover board matters, executive compensation, equity awards and shareholder voting items. Its event filings also describe capital-structure and financing obligations, Regulation FD disclosures, exhibit-based press releases, and formal updates on TransportVehicle-enabled programs across lysosomal storage and neurodegenerative disease indications.
Denali Therapeutics director Timothy Van Hauwermeiren received new equity awards as part of his compensation. He was granted 6,408 shares of common stock in the form of Restricted Stock Units (RSUs), each representing a contingent right to one share of Denali common stock.
All of these RSUs will vest 100% on the earlier of the one-year anniversary of the grant date or the day before Denali’s next annual meeting of stockholders. After this grant, he holds 17,040 RSUs in total, which are all unvested. He was also granted options to purchase 19,226 shares of common stock at an exercise price of $19.66 per share, vesting on the same schedule and expiring in 2036.
Denali Therapeutics director Jennifer E. Cook received equity compensation consisting of restricted stock units and stock options. She acquired 6,408 shares of Common Stock at a price of $0.00 per share as a grant, bringing her direct Common Stock holdings to 32,483 shares.
Each of these 6,408 shares is represented by a restricted stock unit and a contingent right to receive one share of Common Stock, with 100% of the units vesting upon the earlier of the one-year anniversary of the grant date or the day preceding Denali’s next annual meeting of stockholders. She also received a stock option covering 19,226 shares of Common Stock at an exercise price of $19.66 per share, which will vest on the same schedule.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
Denali Therapeutics Inc. director Julian C. Baker received equity-based compensation linked to Baker Brothers funds. The filing reports a grant of 6,408 restricted stock units payable in Denali common stock and 19,226 non-qualified stock options exercisable into common stock at a strike price of $19.66 per share. Both the RSUs and options vest on the earlier of June 3, 2027 or the day prior to Denali’s next annual meeting after June 3, 2026, subject to his continued board service. The transactions are reported as indirect interests of 667, L.P. and Baker Brothers Life Sciences, L.P., with Baker Bros. Advisors LP holding voting and dispositive power. Felix and Julian Baker, the adviser and its general partner all disclaim beneficial ownership beyond their indirect pecuniary interests.
Denali Therapeutics Inc. reported the results of its annual stockholder meeting held on June 3, 2026. Of the 158,675,498 shares of common stock outstanding as of April 9, 2026, 137,986,127 were represented in person or by proxy, representing 86.96% of shares entitled to vote.
Stockholders elected three Class III directors to serve until the 2029 annual meeting: Jennifer Cook, David Schenkein, M.D., and Ryan Watts, Ph.D. Each received more votes “for” than “withheld,” with Ryan Watts, Ph.D. receiving 121,220,572 votes in favor.
Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 137,516,267 votes for, 420,305 against, and 49,555 abstentions. In an advisory vote, stockholders approved the compensation of the named executive officers, with 117,038,745 votes for and 7,088,810 against.
Denali Therapeutics Inc. and Biogen reported topline results from the Phase 2b LUMA study of BIIB122 (DNL151) in early-stage Parkinson’s disease. The study did not meet its primary endpoint of time to confirmed worsening on the MDS-UPDRS Part II and III combined score, and secondary endpoints also showed no benefit versus placebo.
Based on these results, the companies will discontinue development of BIIB122 in idiopathic Parkinson’s disease. Denali will continue to run the separate Phase 2a BEACON study in individuals with Parkinson’s disease who carry a pathogenic LRRK2 variant, with data anticipated in the first half of 2027.
T. Rowe Price Investment Management, Inc. files a Schedule 13G reporting beneficial ownership of 8,519,192 shares of Denali Therapeutics common stock.
The filing states this represents 5.4% of the class as of 03/31/2026, and shows sole voting power of 8,503,878 and sole dispositive power of 8,519,192. The filing is signed on 05/15/2026.
Denali Therapeutics reported a Q1 2026 net loss of $128.4 million, slightly improved from $133.0 million a year earlier, as total operating expenses fell 6% to $137.4 million. Research and development was $103.8 million, reflecting lower small-molecule and manufacturing spend, while general and administrative rose to $33.5 million as the company prepared for commercialization.
Cash, cash equivalents and marketable securities totaled $1.05 billion as of March 31, 2026, supported by $200 million of non‑dilutive funding from a synthetic royalty agreement with Royalty Pharma tied to AVLAYAH sales. AVLAYAH, approved in March 2026 for neurologic manifestations of Hunter syndrome, began U.S. commercial distribution in April. The quarter also added a $36.0 million AVLAYAH‑related milestone as an intangible asset and recorded a $199.6 million liability for the revenue participation right.
Denali Therapeutics reported first quarter 2026 results alongside a major pipeline milestone. The FDA granted accelerated approval for AVLAYAH, a TransportVehicle-enabled therapy for Hunter syndrome, and Denali has begun its U.S. commercial launch with initial patients treated and distribution, support hub, and payer engagement in place.
Net loss was $128.4 million for the quarter ended March 31, 2026, slightly improved from $133.0 million a year earlier, as research and development expenses declined to $103.8 million from $116.2 million. General and administrative expenses rose to $33.5 million, reflecting hiring to support AVLAYAH’s launch.
Denali ended the quarter with approximately $1.05 billion in cash, cash equivalents and marketable securities, helped by $200 million in gross proceeds from a synthetic royalty funding agreement with Royalty Pharma. The company also received a Rare Pediatric Disease Priority Review Voucher and continues to advance a broad neurological and lysosomal disorder pipeline with multiple mid-stage trials and key data readouts expected between 2026 and 2027.
FMR LLC filed an amendment to a Schedule 13G/A reporting beneficial ownership of 6,672,999.32 shares of Denali Therapeutics common stock, representing 4.2% of the class. The filing (Cover CUSIP 24823R105) shows sole dispositive power and is signed May 5, 2026.
Denali Therapeutics Inc. executive Peter Scott Chin filed an amended Form 3 to restate his reported common stock holdings. The filing updates Table I to show direct ownership of 204,402 shares of Denali Therapeutics common stock. It does not report any new stock purchases or sales.